Supriya Lifescience Ltd reports Q2 FY27 revenue of ₹206.30 crore and appoints Mangesh Vaze as COO
- Revenue rose 8.7% sequentially and 3.2% year on year; net profit was ₹29.25 crore, up 21.7% sequentially and down 42.0% year on year.
- Operating margin was approximately 17.4%; no exceptional items were reported.
- Vaze’s appointment as COO and Senior Management Personnel is effective November 6, 2026; the limited review report was unqualified.
